



Jardiance® (empagliflozin) – New indication

- On August 18, 2021, [Boehringer Ingelheim](#) and [Eli Lilly](#) announced the [FDA approval](#) of [Jardiance \(empagliflozin\)](#), to reduce the risk of cardiovascular (CV) death plus hospitalization for heart failure (HHF) in adults with heart failure and reduced ejection fraction.
- Jardiance is also approved:
 - As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM)
 - To reduce the risk of CV death in adults with T2DM and established CV disease.
- The approval of Jardiance for the new indication was based on EMPEROR-Reduced, a randomized, double-blind, placebo-controlled study in 3,730 patients with chronic heart failure (New York Heart Association [NYHA] functional class II-IV) with reduced ejection fraction. Patients received Jardiance or placebo, as adjunct to standard of care heart failure therapy. The primary endpoint was the time to first event of either CV or HHF.
 - Jardiance significantly reduced the relative risk of the primary composite endpoint of time to CV death or HHF by 25% (5.3% absolute risk reduction, 0.75 hazard ratio, 95% CI: 0.65, 0.86; $p < 0.0001$) vs. placebo.
 - Additionally, Jardiance significantly reduced the risk of occurrence of HHF (first and recurrent).
- The recommended dose of Jardiance is 10 mg orally once daily in the morning.
 - For additional glycemic control, the dose may be increased to 25 mg in patients tolerating Jardiance.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.